2 completed, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Optic Nerve Injuries: new trials by email Literature Review of Optic Nerve Injuries trials Research Report on Optic Nerve Injuries
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. Recombinant human erythropoietin 4,000 UI and 2,000 UI, Methylprednisolone succinate 500 mg - Toxic Optic Neuropathy, Treatment | Phase 2 / Phase 3 | Unknown | Asociación para Evitar la Ceguera en México | 18 | 2022-04-05 | 2023-02-28 |
| Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation Wharton jelly derived mesenchymal stem cell, Repetitive electromagnetic stimulation - Methanol Poisoning, Toxic Optic Neuropathy | Phase 3 | Completed | Ankara Universitesi Teknokent | 18 | 2019-04-01 | 2021-05-10 |
| Traumatic Optic Neuropathy Treatment Trial 2 Recombinant human erythropoietin - Traumatic Optic Neuropathy | Phase 3 | Completed | Iran University of Medical Sciences | 93 | 2018-01-06 | 2024-03-08 |
Cranial Nerve Diseases (3) · Cranial Nerve Injuries (3) · Craniocerebral Trauma (3) · Eye Diseases (3) · Nervous System Diseases (3) · Optic Nerve Diseases (3) · Trauma, Nervous System (3) · Wounds and Injuries (3) · Chemically-Induced Disorders (2) · Drug-Related Side Effects and Adverse Reactions (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Radiation Injuries (2)
Control Groups (1) · Epoetin Alfa (1) · Methylprednisolone Hemisuccinate (1)
Ankara Universitesi Teknokent (1) · Asociación para Evitar la Ceguera en México (1) · Iran University of Medical Sciences (1)
Iran (1) · Mexico (1) · Turkey (Türkiye) (1)
Mohsen B Kashkouli, MD (1) · Octavio Turcio-Aceves, MD (1)